Tempus: The Data-Driven Future of Cancer Care is Already Here
Overview: How Tempus’ AI‑Driven Precision Medicine Platform Transforms Oncology Care Tempus is an AI‑enabled precision medicine platform that ingests clinical, molecular, and other real‑world data to inform diagnosis, treatment selection, and research, with a particular focus on oncology. It addresses the persistent challenge that much of healthcare data remains fragmented, unstructured, and under‑utilised, making it […]
Feature Categories
Overview: How Tempus’ AI‑Driven Precision Medicine Platform Transforms Oncology Care
Tempus is an AI‑enabled precision medicine platform that ingests clinical, molecular, and other real‑world data to inform diagnosis, treatment selection, and research, with a particular focus on oncology. It addresses the persistent challenge that much of healthcare data remains fragmented, unstructured, and under‑utilised, making it difficult for clinicians and researchers to consistently translate genomic and clinical signals into actionable decisions at the point of care. By structuring data from electronic health records, pathology, imaging, and comprehensive genomic profiling, Tempus creates a multimodal view of each patient that can be analysed at scale.
On top of this data layer, Tempus applies machine learning models and AI‑driven decision support to surface guideline‑aligned therapies, identify clinical trial options, and highlight patterns in outcomes among similar patients. These capabilities are delivered through a connected suite that includes genomic and liquid biopsy tests, an operating system for precision medicine (Tempus OS), and analytics tools such as Tempus Lens for exploring de‑identified datasets. For clinicians and care teams, this can translate into faster access to interpretable reports, more consistent treatment recommendations, and reduced manual effort in reviewing complex molecular data. For research and development groups, the same infrastructure supports evidence generation and biomarker discovery, helping shorten analysis timelines and improve the quality of data‑driven decisions.
Last checked on 07 May 2026: remains an AI‑focused precision medicine company, with recent expansion of the Tempus Next care‑pathway intelligence platform and continued development of Tempus OS for AI‑driven clinical and research workflows.
What is Tempus?
Tempus is an AI‑enabled precision medicine platform that aggregates and analyses clinical, genomic, and other real‑world data to support diagnosis, treatment selection, and clinical trial matching, particularly in oncology. It is used by hospitals, clinicians, and life sciences researchers who need structured, multimodal patient data and machine learning–based decision support at scale. Tempus is differentiated by its large real‑world data repository, integrated genomic testing and software stack (including Tempus OS), and use of machine learning models trained on longitudinal clinical and molecular datasets to generate evidence and treatment insights.
Why Do Leading Healthcare Teams Trust Tempus?
-
Strategic collaborations with major biopharma companies, including Gilead and Merck, to use Tempus’ multimodal real‑world data and AI platforms for oncology R&D and precision medicine model development.
-
Multi‑year partnerships with leading academic medical centres such as NYU Langone Health and the University of Southern California (Keck Medicine) to integrate Tempus’ molecular profiling, AI‑driven clinical decision support, and trial matching into routine cancer care and research.
-
Recognition by TIME as one of the “10 Most Influential Health and Life Science Companies of 2026,” highlighting the impact of Tempus’ xT CDx FDA‑approved NGS test and its role in advancing data‑driven precision medicine.
-
Centres for Medicare & Medicaid Services (CMS) designation of Tempus’ xT CDx as an Advanced Diagnostic Laboratory Test (ADLT), validating its clinical utility and supporting reimbursement for an FDA‑approved NGS assay.
-
Multiple U.S. FDA 510(k) clearances, including for Tempus Pixel (cardiac imaging analysis), Tempus ECG‑Low EF software (AI‑based ejection fraction risk identification), and the RNA‑based Tempus xR IVD device, demonstrating a track record of regulated AI and IVD products.
-
Operates as a publicly listed company (Nasdaq: TEM), providing audited financial reporting, corporate governance oversight, and transparency expected of a large healthcare technology vendor.
-
Acquisition of Ambry Genetics, expanding Tempus’ genomic testing footprint and strengthening its ability to combine high‑volume clinical sequencing with AI‑driven analytics for precision medicine.
-
Use of de‑identified multimodal datasets and an AI “Lens” platform to support compliant data access for life sciences partners, aligning with real‑world data best practices and privacy‑preserving research models.
-
Validation of Tempus’ algorithms and assays through their use in large‑scale collaborations for biomarker discovery, assay validation, and real‑world evidence generation with leading healthcare and life sciences institutions.
Top 3 Pain Points Tempus Fixes in Healthcare
| Problem | How Tempus Solves It |
|---|---|
| 1. Siloed, fragmented clinical & molecular data | Lens aggregates petabytes of structured and unstructured data into a unified analytics library |
| 2. Slow biomarker discovery and patient stratification | Tempus Loop uses CRISPR screens and modeling tied to RWD to rapidly identify actionable targets. |
| 3. Lack of real-time, guideline-based clinical support | Tempus One & Next embed AI-powered assistance into the EHR, surfacing guideline-matched therapies and care gaps |
Feature Category Summary: Tempus
| Feature Category | Summary | Association (YES, NO, NA) |
|---|---|---|
| Regulatory-Ready | Tempus describes a comprehensive compliance program aligned with HHS‑OIG guidance, AdvaMed Code of Ethics, and California Health & Safety Code, and attests annually to material compliance with the California Code for life‑science companies, including specific policies, training, audits, and monitoring. It operates CLIA‑certified and CAP‑accredited laboratories (cited in investor and product materials) and has at least one FDA‑cleared device (Tempus ECG‑AF AI algorithm for atrial fibrillation risk), indicating experience with FDA device submissions and regulated diagnostics, though full GxP/21 CFR Part 11 system‑validation documentation for the broader platform is not publicly detailed. This constitutes explicit evidence of regulatory‑grade operations and FDA‑cleared AI, even if complete GxP validation artefacts are not public. | YES |
| Clinical Trial Support | Tempus’ TIME Trial Program and TApp trial‑matching platform continuously screen EMR and Tempus sequencing data with NLP models to match patients to interventional and observational cancer trials, with published results showing 216M+ automated searches over two years, 32,532 algorithm‑identified matches, over 6,000 patients referred, and 313 trial consents, dramatically scaling screening and enrollment. Collaborations with GSK and others explicitly state that Tempus’ AI‑enabled platform is used to improve clinical trial design, accelerate enrollment, and identify drug targets, demonstrating end‑to‑end support across design, recruitment, and operational monitoring. | YES |
| Supply Chain & Quality | Public materials focus on diagnostics, AI‑driven clinical decision support, and clinical‑trial solutions; there is no indication that Tempus operates GMP manufacturing, batch‑release QA, serialization, or counterfeit‑detection systems. No public documentation found that Tempus provides supply‑chain integrity or manufacturing‑quality management features as part of its precision‑medicine platform. | NA |
| Efficiency & Cost-Saving | Tempus’s TIME Program publication shows that AI‑driven trial matching screens hundreds of thousands of patients and continuously updates matches, enabling “efficiently identify and recruit patients to clinical trials,” reducing manual prescreening and accelerating enrollment. Industry analyses describe Tempus’ AI as streamlining regulatory and clinical workflows, and partnerships (e.g., with GSK and PBMs) highlight expectations of faster trial activation, improved R&D success rates, and reduced time to bring personalized therapies to patients, implying substantial operational efficiency and cost savings for sponsors and sites. | YES |
| Scalable / Enterprise-Grade | Tempus reports that its TIME Trial Network includes over 40 provider networks and more than 1,800 oncologists, with clinical trial matching running on data from over 1.5 million patients across sites, illustrating large‑scale, multi‑institution deployment. Collaborations with major pharma (e.g., GSK, PBMs, Illumina, Genialis) and use of Tempus’ multimodal data platform to train genomic algorithms confirm that the platform is engineered for enterprise‑grade use in large pharma/biotech, payers, and health systems. | YES |
| HIPAA Compliant | Tempus’ privacy and compliance materials state that it is subject to and complies with U.S. healthcare privacy laws, and external analyses of ethical AI in personalized medicine explicitly describe Tempus as complying with HIPAA and GDPR, using de‑identification and encryption to protect patient data and managing data‑sharing agreements under these frameworks. While detailed HIPAA mappings are not fully public, these sources provide explicit statements that Tempus adheres to HIPAA requirements for PHI handling. | YES |
| Clinically Validated | Tempus has achieved FDA clearance for at least one AI device (Tempus ECG‑AF) that uses AI on ECG data to identify patients at increased risk of atrial fibrillation/flutter, indicating formal clinical validation and regulatory review of its AI technology. In oncology, published studies on the TIME Program and other machine‑learning–based trial matching demonstrate real‑world clinical deployment and impact on trial recruitment, and Tempus’ assays are used in routine clinical care for molecular oncology, collectively supporting clinical validation of its precision‑medicine use cases, though not every algorithm is device‑cleared. | YES |
| EHR Integration | The TIME Program paper and Tempus documentation describe EMR integrations where patient records (including structured codes such as ICD‑10 and LOINC plus unstructured notes) are ingested from participating health‑system EHRs and run through NLP models for trial matching. Tempus One is described as an AI‑enabled clinical assistant available “in the EHR,” able to query patient data across the EHR and surface guideline‑integrated insights, confirming direct clinical‑system integration. | YES |
| Explainable AI | Tempus’ AI tools, particularly in clinical trial matching and decision support, are described as leveraging transparent clinical and molecular criteria, with clinicians able to review why a patient was matched to a given trial based on eligibility rules and biomarkers, as detailed in publications describing the TApp matching logic and nurse review. Analyses of Tempus’ platform in ethical‑AI discussions note that transparency in AI decision‑making and explainable AI solutions are central to maintaining patient and provider trust, and Tempus One is positioned as providing traceable, real‑time insights that clinicians can interrogate within the EHR. Although not every underlying model is fully interpretable, there is explicit emphasis on explainability and clinician‑reviewable logic in its core clinical tools. | YES |
| Real-Time Analytics | Tempus One is described as a generative AI‑powered clinical assistant that provides oncologists with “real‑time insights,” querying EHR and Tempus data at the point of care. The TIME Program’s TApp performs daily algorithmic matching across constantly updated EMR and trial data, generating up‑to‑date trial‑eligibility alerts and enabling rapid trial activation, and clinical‑trial solutions material emphasize continuous screening of patient populations for open trials, indicating near‑real‑time or real‑time analytics over clinical and trial data. | YES |
| Bias Detection | Public Tempus materials and third‑party analyses widely discuss ethical challenges such as bias in genomic datasets and the need for equitable access, and note that Tempus addresses these through strict ethical guidelines, engagement with regulators, and ongoing work in bias mitigation. However, there is no detailed public description of specific in‑product bias‑detection modules, fairness dashboards, or routine reporting of model performance across demographic subgroups; bias is discussed conceptually rather than as a documented, productized feature. No public documentation found for explicit bias‑detection tooling in Tempus’ platforms. | NA |
| Ethical Safeguards | Tempus publishes a detailed California Compliance Statement describing a comprehensive compliance program with written policies, training, monitoring, auditing, and reporting mechanisms aligned with HHS‑OIG guidance and industry ethics codes, and commits to continuous improvement of its compliance program. Ethical‑AI analyses highlight that Tempus addresses privacy, consent, and bias risks by complying with HIPAA/GDPR, de‑identifying data, engaging with regulatory bodies, and building safeguards into its platform, while Tempus One and TIME workflows maintain human‑in‑the‑loop oversight through clinician and nurse review of AI‑generated insights and matches. Together, these constitute documented governance controls, human‑in‑the‑loop review, and policy‑level ethical safeguards, even though fine‑grained configurable use‑case restriction tooling is not publicly detailed. | YES |
Risks & Limitations: Tempus
-
Predictive accuracy depends on the quality, completeness and representativeness of molecular, clinical and sequencing data; gaps or biased cohorts can reduce validity.
-
Outputs are decision-support only — clinicians and researchers must validate recommendations before treatment or trial decisions.
-
Integration with EHRs, lab systems, and site pipelines may require significant IT effort, mapping and workflow alignment.
-
Regulatory, privacy and compliance review is required when AI outputs inform patient selection, therapeutic choice, or trial enrollment; maintain provenance and audit trails.
-
Generalisability risk: models trained on specific populations or platforms may underperform on different populations, assays or sequencing technologies.
-
Model drift and dataset shifts (new assays, therapies, or standards) can degrade performance — ongoing monitoring and retraining are necessary.
-
Explainability limits for complex genomic models can complicate clinical interpretation and regulator discussions; provide clear rationale and evidence for key outputs.
Share This AI Tool
Get a neutral, no obligation view of whether this AI tool fits your portfolio
